Title of Collaborative Activity: |
Cancer Diagnostic Devices Interagency Task Force (CD2) - MOU among NCI, FDA, HRSA |
Description of Collaborative Activity: |
Interagency Task Force: On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient outcomes, quality of life, and reduce health disparities among medically underserved, geographically isolated, and otherwise vulnerable populations. MOU formalizes the establishment of a new interagency task force, the Cancer Diagnostic Devices Interagency Task Force (CD2), which includes representatives from the NCI, FDA, and HRSA. |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
